The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Uric Acid as a Target of Therapy in CKD
Open accessAbstract
The prevalence of chronic kidney disease (CKD) has risen and will continue to rise in the United States and worldwide. This is alarming considering that CKD remains an irreversible condition and patients who progress to chronic kidney failure suffer reduced quality of life and high mortality rates. As such, it is imperative to identify modifiable risk factors to develop strategies to slow CKD progression. One such factor is hyperuricemia. Recent observational studies have associated hyperuricemia with kidney disease. In addition, hyperuricemia is largely prevalent in patients with CKD. Data from experimental studies have revealed several potential mechanisms by which hyperuricemia may contribute to the development and progression of CKD. In this manuscript we offer a critical review of the experimental evidence linking hyperuricemia to CKD, we highlight the gaps in our knowledge on the topic as it stands today, and we review the observational and interventional studies that have examined the potential nephro-protective effect of lowering uric acid in CKD patients . While uric acid may also be linked to cardiovascular disease and mortality in patients with CKD, this review will focus only on uric acid as a potential therapeutic target to prevent kidney disease onset and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.6858 · Cited by 2,909
Molecular identification of a renal urate–anion exchanger that regulates blood urate levels
Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Ho Cha, S., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., et al. (2002) · Nature · doi:10.1038/nature742 · Cited by 1,535
Levey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516
Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
Johnson, R. J., Kang, D.-H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., Tuttle, K. R., Rodriguez-Iturbe, B., Herrera-Acosta, J., & Mazzali, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000069700.62727.c5 · Cited by 1,361
A Role for Uric Acid in the Progression of Renal Disease
Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,304
Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism
Mazzali, M., Hughes, J., Kim, Y.-G., Jefferson, J. A., Kang, D.-H., Gordon, K. L., Lan, H. Y., Kivlighn, S., & Johnson, R. J. (2001) · Hypertension · doi:10.1161/hy1101.092839 · Cited by 1,300
Feig, D. I., Soletsky, B., & Johnson, R. J. (2008) · JAMA · doi:10.1001/jama.300.8.924 · Cited by 914
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Self-citationEffects of Allopurinol on the Progression of Chronic Kidney Disease
Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915833 · Cited by 473
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.028 · Cited by 383
Metadata
- Authors
- Jalal, D. I., Chonchol, M., Chen, W., & Targher, G.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 61
- Issue
- 1
- Pages
- 134-146
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2061170857
- Cited by
- 268
- References
- 64
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Uric Acid as a Target of Therapy in CKD. https://app.cochat.ai/papers/10.1053/j.ajkd.2012.07.021
- The paper
- Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013). Uric Acid as a Target of Therapy in CKD. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2012.07.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.